Skip to Content

GeneThera Inc GTHR

Morningstar Rating
$0.00 −0.01 (99.98%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GTHR is trading at a 35% discount.
Price
$0.01
Fair Value
$9.55
Uncertainty
Extreme
1-Star Price
$8.32
5-Star Price
$3.63
Economic Moat
Hfbkjtp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GTHR is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.01
Day Range
$0.000.00
52-Week Range
$0.000.02
Bid/Ask
$0.01 / $0.10
Market Cap
$35.33
Volume/Avg
4,000 / 9,535

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
2

Valuation

Metric
GTHR
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
GTHR
Quick Ratio
Current Ratio
Interest Coverage
Quick Ratio
GTHR

Profitability

Metric
GTHR
Return on Assets (Normalized)
−15,593.80%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
GTHR
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCpd$550.4 Bil
VRTX
Vertex Pharmaceuticals IncPtfbpg$111.8 Bil
REGN
Regeneron Pharmaceuticals IncFxkqnc$107.9 Bil
MRNA
Moderna IncCdqy$36.3 Bil
ARGX
argenx SE ADRYnyxc$23.0 Bil
BNTX
BioNTech SE ADRZgjc$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncVhbzdy$19.2 Bil
BMRN
Biomarin Pharmaceutical IncXhbkm$16.4 Bil
RPRX
Royalty Pharma PLC Class ASspjcql$13.4 Bil
INCY
Incyte CorpLrmxyqx$13.3 Bil

Sponsor Center